News Image

NYSE:MRK is probably undervalued for the fundamentals it is displaying.

By Mill Chart

Last update: Mar 20, 2024

Discover MERCK & CO. INC. (NYSE:MRK)—an undervalued stock our stock screener has picked out. NYSE:MRK demonstrates solid fundamentals, including health and profitability, all while staying attractively priced. Let's explore the details.

A Closer Look at Valuation for NYSE:MRK

An integral part of ChartMill's stock analysis is the Valuation Rating, which spans from 0 to 10. This rating evaluates diverse valuation factors, including price to earnings and cash flows, while considering the stock's profitability and growth. NYSE:MRK has received a 7 out of 10:

  • 79.10% of the companies in the same industry are more expensive than MRK, based on the Price/Earnings ratio.
  • 85.07% of the companies in the same industry are more expensive than MRK, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of MRK to the average of the S&P500 Index (22.25), we can say MRK is valued slightly cheaper.
  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MRK indicates a somewhat cheap valuation: MRK is cheaper than 77.11% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, MRK is valued cheaply inside the industry as 80.10% of the companies are valued more expensively.
  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The excellent profitability rating of MRK may justify a higher PE ratio.
  • A more expensive valuation may be justified as MRK's earnings are expected to grow with 93.43% in the coming years.

Profitability Examination for NYSE:MRK

ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NYSE:MRK, the assigned 8 is noteworthy for profitability:

  • The Return On Assets of MRK (0.34%) is better than 82.09% of its industry peers.
  • MRK's Return On Equity of 0.97% is amongst the best of the industry. MRK outperforms 83.58% of its industry peers.
  • MRK has a better Return On Invested Capital (3.97%) than 82.09% of its industry peers.
  • The last Return On Invested Capital (3.97%) for MRK is well below the 3 year average (12.63%), which needs to be investigated, but indicates that MRK had better years and this may not be a problem.
  • MRK has a Profit Margin of 0.61%. This is amongst the best in the industry. MRK outperforms 82.59% of its industry peers.
  • The Operating Margin of MRK (6.76%) is better than 80.60% of its industry peers.
  • Looking at the Gross Margin, with a value of 73.53%, MRK belongs to the top of the industry, outperforming 80.10% of the companies in the same industry.

Analyzing Health Metrics

ChartMill assigns a Health Rating to every stock. This score ranges from 0 to 10 and evaluates the different health aspects like liquidity and solvency, both absolutely, but also relative to the industry peers. NYSE:MRK scores a 5 out of 10:

  • MRK has an Altman-Z score of 4.16. This indicates that MRK is financially healthy and has little risk of bankruptcy at the moment.
  • MRK has a better Altman-Z score (4.16) than 79.60% of its industry peers.
  • MRK has a debt to FCF ratio of 3.83. This is a good value and a sign of high solvency as MRK would need 3.83 years to pay back of all of its debts.
  • MRK has a better Debt to FCF ratio (3.83) than 89.05% of its industry peers.

How do we evaluate the Growth for NYSE:MRK?

To evaluate a stock's growth potential, ChartMill utilizes a Growth Rating on a scale of 0 to 10. This comprehensive assessment considers various growth aspects, including historical and estimated EPS and revenue growth. NYSE:MRK has achieved a 4 out of 10:

  • The Earnings Per Share is expected to grow by 50.72% on average over the next years. This is a very strong growth
  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

More Decent Value stocks can be found in our Decent Value screener.

For an up to date full fundamental analysis you can check the fundamental report of MRK

Disclaimer

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.

Back

MERCK & CO. INC.

NYSE:MRK (4/19/2024, 10:32:09 AM)

125.22

-0.01 (-0.01%)

MRK News

News Image5 hours ago - Merck Canada Inc.Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and

/CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab),...

News Image2 days ago - InvestorPlaceComing FDA Approvals Could Send These 3 Drug Stocks Soaring

When it comes to drug stocks, FDA approval can bring years or even decades of steady, high-margin revenue.

News Image3 days ago - InvestorPlace3 Dow Stocks to Buy Now: Q2 Edition

Although the idea of Dow stocks to buy now is patently boring, that could be a positive attribute amid the current backdrop.

News Image4 days ago - The Motley FoolBetter Growth Play: Merck or The Vanguard Growth Index Fund?

Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund?

News Image5 days ago - The Motley FoolMerck Paid $208 Million to Stop Its Drugs From Working. Here's Why That's Bullish.

Being able to stop a drug's unwanted effects could lead to a larger market share.

News Image7 days ago - The Motley Fool1 New Green Flag for Moderna and Merck Stock

There's a new reason to believe that their joint projects are going well.

News Image7 days ago - InvestorPlace7 A-Rated Aggressive Biotech Stocks to Bet On in 2024

We’re using the Portfolio Grader to find the best biotech stocks to buy in today’s market. Each of these stocks get top grades.

News Image8 days ago - Market News VideoSee Which Of The Latest 13F Filers Holds Merck & Co
News Image8 days ago - InvestorPlaceThe $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today

Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.

News Image8 days ago - ChartmillWhen you look at NYSE:MRK, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

MERCK & CO. INC. (NYSE:MRK): good value for what you're paying.

News Image9 days ago - Market News VideoMRK December 2026 Options Begin Trading
News Image11 days ago - Market News VideoMonday Sector Laggards: Energy, Healthcare
MRK Links
Follow us for more